UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neurofibromatosis type 1 and associated malignancies

Current neurology and neuroscience reports, 2009-05, Vol.9 (3), p.247-253

Yohay, Kaleb

2009

Volltextzugriff (PDF)

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

Genetics in medicine, 2023-02, Vol.25 (2), p.100324-100324, Article 100324

2023

Volltextzugriff (PDF)

Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors

The New England journal of medicine, 2024-06, Vol.390 (24), p.2284-2294

2024

Volltextzugriff (PDF)

Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic review

Neurosurgical focus, 2022-05, Vol.52 (5), p.E7-E7

2022

Volltextzugriff (PDF)

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists

Orphanet journal of rare diseases, 2022-02, Vol.17 (1), p.44-44, Article 44

2022

Volltextzugriff (PDF)

The Genetic and Molecular Pathogenesis of NF1 and NF2

Seminars in pediatric neurology, 2006-03, Vol.13 (1), p.21-26

Yohay, Kaleb H.

2006

Volltextzugriff (PDF)

A Thoracentesis with a Neurological Surprise (2638)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models

Journal of neurosurgery, 2014-04, Vol.120 (4), p.854-863

2014

Volltextzugriff (PDF)

Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function

PloS one, 2013-08, Vol.8 (8), p.e73128-e73128

2013

Volltextzugriff (PDF)

Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2

Clinical cancer research, 2009-08, Vol.15 (16), p.5032-5039

2009

Volltextzugriff (PDF)

Patient-Reported Quality of Life Outcomes in Patients With Neurofibromatoses Undergoing Surgery

Plastic and reconstructive surgery. Global open, 2020-10, Vol.8 (9S), p.120-120

2020

Volltextzugriff (PDF)

Identifying Lesions of the Corpus Callosum in Patients with Neurofibromatosis Type I (P8-13.004)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Quality Improvement Project: Number of Neurofibromatosis Type I Patients with Unidentified Bright Objects (UBOs) on MRI that Developed Subsequent Gliomas (P3-9.005)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Development and Management of Glioma in Patients with Neurofibromatosis Type I (P9-8.002)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Genetics in medicine, 2018-07, Vol.20 (7), p.671-682

2018

Volltextzugriff (PDF)

Using Qualitative Interviews to Improve Quantitative Assessments of Quality of Life in Patients with Neurofibromatosis 2 (P7-13.006)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2

NeuroImage clinical, 2014-01, Vol.4 (C), p.258-265

2014

Volltextzugriff (PDF)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

The oncologist (Dayton, Ohio), 2020-07, Vol.25 (7), p.e1109-e1116

2020

Volltextzugriff (PDF)

NF1 Recommendation-Based Care Delivery: A Survey of Patients and Caregivers (P3-7.002)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Awareness and Agreement with Neurofibromatosis Care Expert Recommendations among Neurofibromatosis Specialists (2765)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Identifying Lesions of the Corpus Callosum in Patients With Neurofibromatosis Type 1

Pediatric neurology, 2024-07, Vol.156, p.66-71

2024

Volltextzugriff (PDF)

RARE-02. OBSERVATIONAL REGISTRY STUDY OF TREATMENT PRACTICES AND LONG-TERM OUTCOMES OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMAS (PN) INITIATING SELUMETINIB IN REAL-WORLD PRACTICE IN THE UNITED STATES (US): STUDY DESIGN AND METHODOLOGY

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i33-i33

2023

Volltextzugriff (PDF)

CTNI-65. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE TUMORS: INTERIM RESULTS OF THE BRIGATINIB TREATMENT ARM

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii88-vii88

2022

Volltextzugriff (PDF)

NFS-11. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Volltextzugriff (PDF)

Neurofibromatosis types 1 and 2

The Neurologist (Baltimore, Md.), 2006-03, Vol.12 (2), p.86-93

Yohay, Kaleb

2006

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(53)
Buchkapitel
(1)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neurofibromatosis type 1 and associated malignancies

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors

Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic review

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists

The Genetic and Molecular Pathogenesis of NF1 and NF2

A Thoracentesis with a Neurological Surprise (2638)

Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models

Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function

Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2

Patient-Reported Quality of Life Outcomes in Patients With Neurofibromatoses Undergoing Surgery

Identifying Lesions of the Corpus Callosum in Patients with Neurofibromatosis Type I (P8-13.004)

Quality Improvement Project: Number of Neurofibromatosis Type I Patients with Unidentified Bright Objects (UBOs) on MRI that Developed Subsequent Gliomas (P3-9.005)

Development and Management of Glioma in Patients with Neurofibromatosis Type I (P9-8.002)

Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Using Qualitative Interviews to Improve Quantitative Assessments of Quality of Life in Patients with Neurofibromatosis 2 (P7-13.006)

Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

NF1 Recommendation-Based Care Delivery: A Survey of Patients and Caregivers (P3-7.002)

Awareness and Agreement with Neurofibromatosis Care Expert Recommendations among Neurofibromatosis Specialists (2765)

Identifying Lesions of the Corpus Callosum in Patients With Neurofibromatosis Type 1

RARE-02. OBSERVATIONAL REGISTRY STUDY OF TREATMENT PRACTICES AND LONG-TERM OUTCOMES OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMAS (PN) INITIATING SELUMETINIB IN REAL-WORLD PRACTICE IN THE UNITED STATES (US): STUDY DESIGN AND METHODOLOGY

CTNI-65. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE TUMORS: INTERIM RESULTS OF THE BRIGATINIB TREATMENT ARM

NFS-11. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS

Neurofibromatosis types 1 and 2

Suchergebnisse filtern